The estimated Net Worth of John Simard is at least $41.2 Million dollars as of 15 October 2021. Mr. Simard owns over 50,000 units of XBiotech Inc stock worth over $24,735,884 and over the last 9 years he sold XBIT stock worth over $5,644,028. In addition, he makes $10,810,400 as Chairman of the Board, President, Chief Executive Officer, and Founder at XBiotech Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Simard XBIT stock SEC Form 4 insiders trading
John has made over 10 trades of the XBiotech Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 50,000 units of XBIT stock worth $657,500 on 15 October 2021.
The largest trade he's ever made was exercising 500,000 units of XBiotech Inc stock on 22 March 2021 worth over $3,750,000. On average, John trades about 54,091 units every 73 days since 2016. As of 15 October 2021 he still owns at least 3,823,166 units of XBiotech Inc stock.
You can see the complete history of Mr. Simard stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Simard biography
John Simard serves as Chairman of the Board, President, Chief Executive Officer, Founder of the Company. Prior to XBiotech, he was founder and Chief Executive Officer of CTL ImmunoTherapies Corp., a developer of therapeutic vaccines to treat cancer and chronic infectious disease; he also founded AlleCure Corp., of Valencia, California, a developer of allergy treatments and immune modulating therapies. In 2001, AlleCure and CTL ImmunoTherapies merged to form MannKind Corp., where Mr. Simard served as Corporate Vice President and a board member. Mr. Simard holds a degree in Biochemistry from the University of Saskatchewan and attended graduate studies in Medical Biophysics/Immunology at the University of Toronto. He has over 140 issued and pending patents related to cancer therapy, therapeutic vaccines and therapeutic antibodies, as well as a substantial number of peer-reviewed scientific publications and the textbook “Immune Response Genes.”
What is the salary of John Simard?
As the Chairman of the Board, President, Chief Executive Officer, and Founder of XBiotech Inc, the total compensation of John Simard at XBiotech Inc is $10,810,400. There are no executives at XBiotech Inc getting paid more.
How old is John Simard?
John Simard is 57, he's been the Chairman of the Board, President, Chief Executive Officer, and Founder of XBiotech Inc since 2005. There are 5 older and 4 younger executives at XBiotech Inc. The oldest executive at XBiotech Inc is Peter Libby, 73, who is the Independent Director.
What's John Simard's mailing address?
John's mailing address filed with the SEC is 5217 WINNEBAGO LANE, , AUSTIN, TX, 78744.
Insiders trading at XBiotech Inc
Over the last 9 years, insiders at XBiotech Inc have traded over $50,443,920 worth of XBiotech Inc stock and bought 1,428,502 units worth $11,921,113 . The most active insiders traders include Street Financial S.A. Bay, Fondation Rennes, and W Thorpe Mckenzie. On average, XBiotech Inc executives and independent directors trade stock every 48 days with the average trade being worth of $1,053,782. The most recent stock trade was executed by W Thorpe Mckenzie on 16 December 2021, trading 250,000 units of XBIT stock currently worth $2,500,000.
What does XBiotech Inc do?
xbiotech is developing a first-in-class monoclonal antibody (mabp1) to inhibit chronic inflammation. chronic (sterile) inflammatory responses are involved in the progression of many serious and common diseases. mabp1 is being investigated in many important areas of medicine, including: cancer, leukemia (phase 1); type 2 diabetes (phase2); psoriasis (phase 2); and vascular disease (phase 2). mabp1 is a true human™ antibody cloned from a natural human immune response and—unlike currently marketed antibodies—it has not undergone any modification to alter its function. it has exhibited the best potential tolerability and safety during the clinical trials. xbiotech has established a current good manufacturing practices (cgmp) program to commercialize its lead product candidate. the company has purchased land and designed a commercial-scale plant with 25,000l total bioreactor capacity. construction of the facility is planned to commence in 4th quarter 2011..
What does XBiotech Inc's logo look like?
Complete history of Mr. Simard stock trades at XBiotech Inc
XBiotech Inc executives and stock owners
XBiotech Inc executives and other stock owners filed with the SEC include:
-
John Simard,
Chairman of the Board, President, Chief Executive Officer, Founder -
John Simard,
Founder, Pres, CEO & Chairman -
Sushma Shivaswamy,
Chief Scientific Officer -
Queena Han,
Vice President - Finance and Human Resources, Secretary -
Dr. Sushma Shivaswamy,
Chief Scientific Officer -
Queena Han CPA, B.A., CPA, C.G.A.,
VP of Fin. & HR and Sec. -
W. Thorpe McKenzie,
Independent Director -
Donald MacAdam,
Independent Director -
Peter Libby,
Independent Director -
Jan-Paul Waldin,
Lead Independent Director -
Lisa Simard,
Director of Corp. Strategy - XBiotech USA, Inc. -
BenjamÃn Guzmán,
Sr. VP of Corp. Strategy & Fin. -
Daniel Vasella,
Director -
Trey Benson,
VP of Commercial Development -
Kelly Thornburg,
SVP of Operations -
Fabrizio Bonanni,
Director -
Dawn Mc Collough,
VP Clinical Operations -
Michael Stecher,
Medical Director -
Kalidip Choudhury,
VP of Business Development -
James Scott Whitehurst,
Chief Financial Officer -
Thomas Gut,
10% owner -
Benjamin Guzman,
Sr.VP Corp. Strategy & Finance -
Fondation Rennes,
10% owner -
Street Financial S.A. Bay,
10% owner